Nahleh Zeina, Girnius Saulius
Breast Oncology Program, Division of Hematology-Oncology, University of Cincinnati, Cincinnati, OH 45267, USA.
Nat Clin Pract Oncol. 2006 Aug;3(8):428-37. doi: 10.1038/ncponc0564.
The incidence of male breast cancer (MBC) is rising; however, mortality due to MBC has not changed, unlike female breast cancer. This lack of change is mostly attributable to a lack of major progress in the understanding and treatment of the disease. The treatment of MBC has been extrapolated from the knowledge of female breast cancer, despite the multiple differences in the pathogenesis, biology and genetics of these two disease entities, especially the differences with regard to the role of male hormones as well as estrogens in MBC compared with female disease. Although major advances in hormonal manipulation for the treatment of breast cancer are being developed, an improved understanding of the potential differences between male and female breast cancer is essential, as this would provide new opportunities for therapeutic intervention and probable improved outcome for MBC. This review aims at highlighting the major differences between male and female breast cancer with an emphasis on hormonal therapy, and discusses some of the recent advances in MBC.
男性乳腺癌（MBC）的发病率正在上升；然而，与女性乳腺癌不同，MBC导致的死亡率并未改变。这种未改变的情况主要归因于在该疾病的认识和治疗方面缺乏重大进展。尽管这两种疾病实体在发病机制、生物学和遗传学方面存在诸多差异，尤其是与女性疾病相比，男性激素以及雌激素在MBC中的作用有所不同，但MBC的治疗一直是从女性乳腺癌的知识推断而来。尽管在乳腺癌激素治疗方面正在取得重大进展，但更好地理解男性和女性乳腺癌之间的潜在差异至关重要，因为这将为治疗干预提供新机会，并可能改善MBC的治疗结果。本综述旨在突出男性和女性乳腺癌之间的主要差异，重点是激素治疗，并讨论MBC的一些最新进展。
